logo
Developers seek to build 750 affordable rentals in Kapolei

Developers seek to build 750 affordable rentals in Kapolei

Yahooa day ago

A master-planned community long envisioned for Kapolei could begin to take shape early next year with initial homes that help ease Oahu's short supply of affordable rental housing.
Developers of the roughly 500-acre project known as Kapolei West between the City of Kapolei and Ko Olina Resort &Marina have advanced plans to produce an initial 17-acre subdivision of 750 rental apartments that would be affordable in perpetuity to households with low and moderate incomes.
Affiliates of Utah-based firm The Wasatch Group are aiming to start construction in February and finish homes in four phases from August 2027 to July 2028.
'We're very excited about getting going, ' said Kip Sheppard, head of Wasatch affiliate Laulima Affordable Housing LLC developing the 750-unit project to be named Aloha Aina. 'It's been a long time coming.'
Aloha Aina's four phases involve 70 units for low-income seniors, 180 units for low-income families and two phases with a combined 500 units for moderate-income households.
The first phase, according to Sheppard, could either be the piece for seniors or 236 units for moderate-income households, depending on whether low-cost financing can be obtained from the state later this year.
Two pools, community gardens, two clubhouses and residential units in eight buildings rising up to six stories are part of the Aloha Aina project, which is expected to cost $447 million and would provide tenants with the lowest utility rates of any West Oahu community due in part to photovoltaic power and construction materials, according to the developer.
If successful, Wasatch will start forming an initial piece of Kapolei West that was first envisioned more than 30 years ago and was previously pursued by multiple developers.
The property for decades was among thousands of acres of sugarcane plantation lands in the area owned by Campbell Estate programmed to become part of Kapolei as Oahu's secondary urban center.
An original version of the community later dubbed Kapolei West by the estate was proposed in 1991 by Ko Olina's initial developer Herbert Horita, who had an option to buy the roughly 500-acre site bordering the resort.
Horita's plan was to produce 3, 500 homes around a second golf course for the resort. But development of Ko Olina stalled under Horita due to the bursting of the Japanese investment bubble followed by an economic downturn in Hawaii that lasted for most of the 1990s.
In 2001 developer Jeff Stone, who with partners acquired the then-mostly undeveloped resort in 1998, announced plans to purchase 324 acres of the Kapolei West site to produce Seaside at Kapolei with 2, 900 homes, a golf course and a 33-acre commercial center.
Financing challenges in the wake of the Sept. 11, 2001, terrorist attacks derailed Stone's plan.
An affiliate of Campbell Estate's successor, James Campbell Co., several years later obtained land-use and zoning approvals for Kapolei West allowing up to 2, 500 homes, a 23-acre regional mall, a golf course and 25 acres of park space.
In 2016 a Chinese company paid Campbell Co. $103 million for the Kapolei West site. But China Oceanwide Holdings Ltd. failed to develop the land amid a Chinese-government clampdown on overseas investment, and in 2022 sold the property to Wasatch for $75 million, according to property records.
As part of land-use approvals, the property owner is required to make 30 % of all homes affordable to low and moderate-income households, with 10 % being affordable to households earning no more than 80 % of the median income and 20 % affordable to households earning no more than 120 % of the median income.
Aloha Aina would satisfy this requirement, though Wasatch is aiming to make its 10 % share, or 250 homes, affordable to households earning no more than 60 % of the median income, including 18 reserved for households earning half that.
Apartments throughout Aloha Aina mostly will range in size from 606 to 1, 218 square feet with one, two or three bedrooms in addition to a half-dozen, 493-square-foot studios.
Maximum monthly rents for tenants earning up to 60 % of the median income can be $1, 596 for studios, $1, 710 for one-bedroom units, $2, 052 for two-bedroom units and $2, 371 for three-bedroom units under state guidelines.
The income level this year equates to $63, 840 for a single person, $72, 960 for a couple and $91, 200 for a family of four.
The other 500 units could have tenants earning up to twice as much, or $127, 680 for a single person, $145, 920 for a couple and $182, 400 for a family of four. Corresponding maximum monthly rents could range from $3, 192 for a studio up to $4, 743 for a three-bedroom apartment.
To finance the 250 low-income apartments, Aloha Aina's developer has applied for about $130 million in combined tax-free bond financing, a low-interest loan and tax credits from the Hawaii Housing Finance and Development Corp., a state agency that helps finance affordable housing.
Such financing is awarded to developers on a competitive basis. If Wasatch's application is approved, the developer intends to proceed first with the 70 units for low-income seniors to be called Maluhia followed by the 180 units for low-income families to be named The Hoku.
The developer also is seeking exemptions from having to pay certain city fees estimated to total about $4.4 million, including a $2 million wastewater system charge, $1.3 million in building permit fees and a $933, 750 road improvement fee.
HHFDC has yet to act on the developer's applications.
If the requested financing is not approved this year, Wasatch intends to proceed first with the moderate-income portions of the project.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Business Upturn

time29 minutes ago

  • Business Upturn

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development Plans Intellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program Intellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 ( KLKB1 ) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors:Brittany ChavesSenior Manager, Investor Relations [email protected]

HAVEN's Summer 2025 Collection Centers on the Pacific Northwest's Terrain
HAVEN's Summer 2025 Collection Centers on the Pacific Northwest's Terrain

Hypebeast

timean hour ago

  • Hypebeast

HAVEN's Summer 2025 Collection Centers on the Pacific Northwest's Terrain

Vancouver-based labelHAVENhas unveiled a coastal campaign for its Summer 2025 collection, returning with a capsule of essentials designed for the warm days and cool nights of Summer in the Pacific Northwest. Utilizing cotton-linen gabardines, Japan denim, and lightweight Super 140s wool, the label offers a range of core garments characterized by the label's functional, minimalist ethos. HAVEN opts for a light and neutral color palette inspired by the woodland coast of Vancouver, led by tones of beige, sage green, brown, off-white, and indigo. The collection is anchored by matching linen gabardine sets, comprising a work jacket that reinterprets the classic military BDU (battle dress uniform) garments. Offered in a dark brown and beige colorway, the jacket's ergonomic tailoring and underarm gussets elevate the utilitarian design with contemporary elegance. In indigo and white, Japanese linen denim shirts and trousers offer a cooling feel and soft hand. The denim Helix Pant features twisted side seams for a sculpted fit and added mobility, and functional details, like slant hand pockets, storm welt back pockets, and snap-adjustable waist tabs. HAVEN tops the collection off with wool Summer shirting, including wool versions of the aforementioned denim shirts in beige, green, and brown checks. Utilizing Super 140s wool, known for its ultra-fine quality, the collection also offers short-sleeve camp collar shirts in the same three colorways. See the gallery above for a closer look at the campaign. HAVEN's Summer 2025 Delivery 1 is out now at the brand'swebsiteand physical store.

Exclusive: Zorro clinches $20M Series A for ICHRA health plans
Exclusive: Zorro clinches $20M Series A for ICHRA health plans

Axios

time2 hours ago

  • Axios

Exclusive: Zorro clinches $20M Series A for ICHRA health plans

Health benefits provider Zorro raised $20 million in Series A funding led by Entrée Capital, CEO Guy Ezekiel tells Axios exclusively. Why it matters: As employers wrestle with rising health plan costs, individual coverage health reimbursement arrangements (ICHRAs) are gaining steam. Driving the news: Launched in 2020, ICHRAs were enabled by a Trump-era rule letting employers reimburse employees tax-free for individual health insurance instead of offering group plans. After a slow start, rule clarifications and compliance tools made them more accessible to midsized employers. Follow the money: Existing backers Pitango and 10D joined the round, which will be used to scale operations and improve support for employers. The Series A brings Zorro to $31.5 million total raised. The company is not yet profitable. How it works: New York City-based Zorro replaces traditional group plans with defined-contribution models. Employers set a budget; employees use Zorro's AI engine to select personalized plans, and brokers get real-time tools to compare group plans versus ICHRA-based options. When it onboards an employer, Zorro asks them to send their benefits roster from the previous year, asks about quality and budget priorities for the upcoming year, and helps predict what benefits employees might want next. Zorro has "several thousand" lives on the platform, per Ezekiel. Between the lines: Zorro's pitch hinges not just on cost control but on its ability to shift complex decision-making from HR to software — claiming that 75% of users enroll without human help. What they're saying: "We're giving the employer a line of sight to how his upcoming year is going to look," says Ezekiel. Reality check: While ICHRAs are gaining traction, they remain a small fraction of the employer market. Zorro's long-term success depends on widespread broker adoption and employee trust in AI-led benefit decisions. State of play: A February Bailey's report predicted the debut of several new ICHRA startups in 2025. Several others have secured recent funding. In April, Thatch raised $40 million in Series B funding led by Index Ventures and Venteur Health Insurance raised a $20 million Series A led by Informed Ventures and American Family Ventures. Remodel Health last December collected more than $100 million in a round led by Oak HC/FT and Hercules Capital.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store